ArticleNPJ digital medicine2026
Physics-informed deep learning enables reliable and scalable organoid quantification for drug screening via OCT.
Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [Current status and challenges of artificial intelligence and organoid technologies in precision diagnosis and treatment of gastrointestinal stromal tumors].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Patient-derived organoids (PDOs) hold transformative potential for personalized medicine by recapitulating patient-specific drug responses. While Optical Coherence Tomography (OCT) is ideal for monitoring these responses, its translation into high-throughput screening (HTS) is hindered by a segmentation accuracy-throughput bottleneck. Existing solutions fail to meet clinical demands: accurate 3D approaches are prohibitively slow, while emerging foundation models lack sensitivity to minute, low-contrast OCT targets. Conversely, fast 2D models suffer from background noise and unstable performance across varying scales. To bridge this gap, we propose DICE-2DSeg, a physics-informed, graph-enhanced framework. By synergizing OCT-inspired intra-slice coherent enhancement with graph-based inter-slice context aggregation, our method ensures robust quantification. Validated on 93 volumes across diverse cancer types and drugs, DICE-2DSeg demonstrates exceptional robustness. Specifically, our high-throughput variant achieves a 14-fold speedup over nnUNet3D while retaining 93.65% of its accuracy. Crucially, it exhibits superior multi-scale consistency, establishing a new state-of-the-art for challenging drug-responsive remnants (0-100 μm) while maintaining high fidelity for massive clusters (> 100 μm). By resolving the conflict between precision, scalability, and scale-invariance, DICE-2DSeg provides a technical enabling step for automated, large-scale PDO drug screening.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.